Daiichi Sankyo Company Limited and India's largest pharmaceutical company, Ranbaxy Laboratories Limited announced a synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the companies’ second marketing synergy in the ASEAN region.
Ranbaxy will market Cravit (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical Sdn Bhd (hereafter, First Pharma) in Malaysia. Daiichi Sankyo and First Pharma have agreed to transfer the marketing rights of Cravit (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo’s marketing partner for other products (except Cravit) it had in-licensed from Daiichi Sankyo.
“We are pleased to announce another synergistic business development with Ranbaxy in ASEAN,” said Joji Nakayama, president and CEO of Daiichi Sankyo. “Our previous collaboration, in Singapore, has already proved Ranbaxy’s marketing excellence in this strongly emerging region. We will continue to explore further initiatives with Ranbaxy to serve diversifying medical needs.”
Commenting on the development, Arun Sawhney, CEO and managing director of Ranbaxy, said, “Ranbaxy has been acknowledged as a premier branded generics company in Malaysia and is well known for its innovative marketing strategies and professional approach. This is in addition to Ranbaxy’s reputation of providing high quality, safe and efficacious products to customers, since 1984. The synergy between Ranbaxy and Daiichi Sankyo will allow us to introduce innovator products from Daiichi Sankyo, complementing our own portfolio of branded generics to bring a wider range of medicines to Doctors and Patients. I am confident that our Malaysian team will enhance the level of customer satisfaction through this synergy.”
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. Originally discovered by Daiichi Sankyo, levofloxacin was first launched in Japan in 1993 under the brand name Cravit. Levofloxacin is currently available in more than 120 countries worldwide.
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
Ranbaxy Laboratories Limited, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.